Now Enrolling in Bladder Cancer

Phase II • NCT05645692 • BO44157

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 (tobemstomig, an anti-PD1-LAG3 bispecific antibody) Alone or in Combination With Tiragolumab (anti-TIGIT antibody) Versus Atezolizumab (anti-PD-L1 antibody) in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

SCHEMA

Key Eligibility Criteria

- Locally advanced or metastatic UC
- No prior treatment for advanced/metastatic setting
- No prior CIT
- Known PD-L1 status
- Platinum-ineligible

  ECOG PS 0 with baseline GFR ≥15 mL and ≤30 mL

  ECOG PS 1 or 2 with baseline GFR ≥15 and ≤45

  ECOG 0-2 with G>2 neuropathy

  Patients for whom chemotherapy was not deemed appropriate

Stratification Factors

- PD-L1 expression*: positive (TAP ≥5%) vs negative TAP (<5%)
- Baseline liver metastases: yes or no (capped at 15%)
- ECOG PS 0 or 1 vs 2


R
1:1:1
n=240
Arm 1:
Control: atezolizumab 1200 mg IV Q3W
Arm 2:
tobemstomig 600 mg IV Q3W
Arm 3:
tobemstomig 600 mg IV Q3W +
tiragolumab 600 mg IV Q3W
Loss of clinical benefit or unacceptable toxicity

TAP: Tumor area positivity with score positive (TAP ≥5%) vs negative (TAP <5%) with TAP assessed as the percentage of stained tumor and immune cells within the total tumor area *Per VENTANA PD-L1 (SP263) companion diagnostic assay; Q3W: every three weeks

STUDY ENDPOINTS

Primary Outcome Measure:

- Investigator-assessed confirmed ORR

Selected Secondary Outcome Measures:

- PFS
- OS
- DoR
- DCR
- Safety

Find out if your bladder cancer patients are eligible for enrollment. For more information

Visit:
ClinicalTrials.gov

Email:
global.rochegenentechtrials@roche.com

ClinicalTrials.gov Identifier: NCT05645692

Information is consistent with ClinicalTrials.gov as of April 13, 2023. Products under investigation have not been approved for use outside of the clinical trial setting. This information is presented only for the purposes of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.

2023 F. Hoffmann-La Roche Ltd. All rights reserved M-ES-00009839